Genetics of schizophrenia: Implications for treatment

Expert Review of Neurotherapeutics

Volumn 4, Issue 4, 2004, Pages 725-731

  Northup, Abbegail ^b   Nimgaonkar, Vishwajit L ^a,b  

^a WPIC   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Clozapine; Genetics; Schizophrenia treatment

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; RISPERIDONE;

5 HYDROXYTRYPTAMINE RECEPTOR 2A GENE; 5 HYDROXYTRYPTAMINE RECEPTOR 2C GENE; ALLELE; ALPHA 1A ADRENERGIC RECEPTOR GENE; ALPHA 2A ADRENREGIC RECEPTOR GENE; CLINICAL TRIAL; DISABILITY; DNA POLYMORPHISM; DOPAMINE RECEPTOR D1 GENE; DOPAMINE RECEPTOR D2 GENE; DOPAMINE RECEPTOR D3 GENE; GENE; GENE LINKAGE DISEQUILIBRIUM; GENE MAPPING; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENETICS; HERITABILITY; HISTAMINE H1 RECEPTOR GENE; HISTAMINE H2 RECEPTOR GENE; HUMAN; META ANALYSIS; MULTIFACTORIAL INHERITANCE; PHARMACOGENOMICS; REVIEW; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTIPSYCHOTIC AGENTS; HUMANS; LINKAGE (GENETICS); SCHIZOPHRENIA;

EID: 3042697129     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.4.4.725     Document Type: Review

References (45)

1. Gottesman I. Schizophrenia Genesis: The Origins of Madness. WH Freeman, NY, USA (1991). Good introduction to schizophrenia.
2. Moldin SO. The maddening hunt for madness genes. Nature Genetics 17, 127-129 (1997).
3. Levinson DF, Holmans P, Straub RE et al. Multicenter linkage study of schizophrenia candidate regions on chromosomes 5q, 6q, 10p and 13q: schizophrenia linkage collaborative group III. Am. J. Hum. Genet. 67(3), 652-663 (2000).
4. Levinson DF, Levinson MD, Segurado R, Lewis CM. Genome scan meta-analysis of schizophrenia and bipolar disorder, part I: methods and power analysis. Am. J. Hum. Genet. 73(1), 17-33 (2003).
5. Nimgaonkar V. In defense of genetic association studies. Mol. Psychiatry 2, 275-277 (1997).
6. Baron M. Genetics of schizophrenia in the new millenium: progress and pitfalls. Am. J. Hum. Genet. 68(2), 299-312 (2001).
7. O'Donovan MC, Owen MJ. Candidate Gene-association studies of schizophrenia. Am. J. Hum. Genet. 65(3), 587-592 (1999). Cogent defense of candidate gene studies.
8. Crowe RR. Candidate genes in psychiatry: an epidemiological perspective. Am. J. Hum. Genet. (2), 74-77 (1993).
9. Harrison PJ, Owen MJ. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 361(9355), 417-419 (2003). Update on candidate gene studies in schizophrenia, with a hypothesis explaining the functional implications.
10. Chowdari KV, Mirnics K, Semwal P et al. Association and linkage analyses of RGS4 polymorphisms in schizophrenia. Hum. Mol. Genet. 11(12), 1373-1380 (2002).
11. Williams NM, Preece A, Spurlock G et al. Support for RGS4 as a susceptibility gene for schizophrenia. Biol. Psychiatry 55(2), 192-195 (2004).
12. Morris DW, Rodgers A, McGhee KA et al. Confirming RGS4 as a susceptibility gene for schizophrenia. Am. J. Hum. Genet. 125B(1), 50-53 (2004).
13. Chumakov I, Blumenfeld M, Guerassimenko O et al. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc. Natl Acad. Sci. USA 99(21), 13675-13680 (2002).
14. Stefansson H, Sigurdsson E, Steinthorsdottir V et al. Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet. 71(4), 877-892 (2002).
15. Stefansson H, Sarginson J, Kong A et al. Association of neuregulin 1 with schizophrenia confirmed in a Scottish population. Am. J. Hum. Genet. 72(1), 83-87 (2003).
16. Williams NM, Preece A, Spurlock G et al. Support for genetic variation in neuregulin 1 and susceptibility to schizophrenia. Mol. Psych. 8(5), 485-487 (2003).
17. Straub RE, MacLean CJ, Ma Y et al. Genome-wide scans of three independent sets of 90 Irish multiplex schizophrenia families and follow-up of selected regions in all families provides evidence for multiple susceptibility genes. Mol. Psych. 7(6), 542-559 (2002).
18. Schwab SG, Knapp M, Mondabon S et al. Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. Am. J. Hum. Genet. 72(1), 185-190 (2003).
19. Morris DW, McGhee KA, Schwaiger S et al. No evidence for association of the dysbindin gene with schizophrenia in an Irish population-based study. Schizophr. Res. 60(2-3), 167-172(2003).
20. van den Oord EJ, Sullivan PF, Jiang Y et al. Identification of a high-risk haplotype for the dystrobrevin binding protein 1 (DTNBP1) gene in the Irish study of high-density schizophrenia families. Mol. Psych. 8(5), 499-510 (2003).
21. Wright AF, Carothers AD, Pirastu M. Population choice in mapping genes for complex diseases. Nature Genetics 23(4), 397-404 (1999).
22. Risch NJ. Searching for genetic determinants in the new millennium. Nature 405(6788), 847-856, (2000).
23. Altmuller J, Palmer LJ, Fischer G, Scherb H, Yjst M. Genomewide scans of complex human diseases, True linkage is hard to find. Am. J. Hum. Genet. (2004) (In Press).
24. Sklar P, Schwab SG, Williams NM, Daly M et al. Association analysis of NOTCH4 loci in schizophrenia using family and population-based controls. Nature Genetics 28(2), 126-128 (2001).
25. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487-491 (1999). Basic review of pharmacogenomics.
26. 2A receptor gene. Lancet 346(8970), 281-282 (1995).
27. 2A receptor and clinical response to clozapine. Neurosci. Lett. 217(2-3), 177-178 (1996).
28. Scharfetter J. Dopamine receptor polymorphisms and drug response in schizophrenia. Pharmacogenomics 2(3), 251-261 (2001).
29. Arranz MJ, Mancama DT, Kerwin RW. Pharmacogenetic and pharmacogenomic research in psychiatry: current advances and clinical applications. Curr. Pharmacogenomics 1(3), 151-158(2003). A clear and comprehensive review of pharmacogenomics in relation to psychiatry.
30. Potkin SG, Basile VS, Jin Y et al. D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Mol. Psychiatry 8(1), 109-113 (2003).
31. Malhotra AK, Buchanan RW, Kim S et al. Allelic variation in the promoter region of the dopamine D2 receptor gene and clozapine response. Schizophr. Res. 36(1-3), 92-93 (1999).
32. Scharfetter J, Chaudhry HR, Hornik K et al. Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patients. Eur. Neuropsychopharmacol. 10(1), 17-20 (1999).
33. Lin CH, Tsai SJ, Yu YW et al. No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population. Neuroreport 10(1), 57-60 (1999).
34. Masellis M, Basile V, Meltzer HY et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 19(2), 123-132 (1998).
35. 2A receptor gene. Am. J. Psychiatry 159(9), 1593-1595 (2002).
36. 2C receptor gene. Neuroreport 7(1), 169-172 (1995).
37. Schumacher J, Schulze TG, Wienker TF, Rietschel M, Nothen MM. Pharmacogenetics of the clozapine response. Lancet 356(9228), 506-507 (2000).
38. Yu YW, Tsai SJ, Lin CH, Hsu CP, Yang KH, Hong CJ. Serotonin-6 receptor variant (C267T) and clinical response to clozapine. Neuroreport 10(6), 1231-1233 (1999).
39. Tsai SJ, Wang YC, Yu Younger WY, Lin CH, Yang KH, Hong CJ. Association analysis of polymorphism in the promoter region of the α-2a-adrenoceptor gene with schizophrenia and clozapine response. Schizophr. Res. 49(1-2), 53-58 (2001).
40. Bolonna AA, Arranz MJ, Munro J et al. No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response. Neurosci. Lett. 280(1), 65-68 (2000).
41. Mancama D, Arranz MJ, Munro J et al. Investigation of promoter variants of the histamine 1 and 2 receptors in schizophrenia and clozapine response. Neurosci. Lett. 333(3), 207-211 (2002).
42. 2A receptor T102C polymorphism and schizophrenia. Lancet 347(9018), 1831-1832 (1996).
43. Malhotra AK, Kennedy JL, Collier DA, Rietschel M. Pharmacogenetics in psychiatry satellite meeting at the American College of Neuropsychopharmacology 2000. Neuropsychopharmacology 26(1), 123-127 (2002).
44. Rietschel M, Kennedy JL, Macciardi F, Meltzer HY. Application of pharmacogenetics to psychotic disorders, the first consensus conference. The Consensus Group for Outcome Measures in Psychoses for Pharmacological Studies. Schizophr. Res. 37(2), 191-196 (1999).
45. Basile VS, Masellis M, Potkin SG, Kennedy JL. Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum. Mol. Genet. 11(20), 2517-2530 (2002).